
Redditor asks, ‘why don't Indians floss their teeth'; falls into a rabbit hole of oral health marketing, Ayurveda, and cultural clashes
iStock
For generations, brushing twice a day was the gold standard, and that too only in urban households.
Ayurveda's Ancient Tools vs. Modern Western Habits
You Might Also Like:
Are you clinging to your toothbrush? Dentist Reveals the ideal time limit for a healthy smile
The High Cost of Clean Gums
iStock
Accessibility and affordability remain significant barriers for flossing habit in India.
A Change in the Air
You Might Also Like:
Not brushing before bed? Harvard doctor warns of 3 terrifying heart risks
It all started with a seemingly innocent question posted on r/AskIndia: 'Why is flossing your teeth not common in India?' The poster added that they often see Americans promote flossing as an essential part of nighttime oral hygiene, but rarely, if ever, encounter an Indian who does the same. The question, surprisingly, struck a nerve — what began as a health query turned into a cultural deep-dive, complete with historical context, economic critique, and even a dash of Ayurveda.What emerged from the flood of responses was not just the answer to one Redditor's curiosity, but a reflection of how deeply our habits are shaped by culture and commerce — and how that could be shifting.One user cut to the chase: 'Marketing,' they wrote. 'Even in the West, flossing only became a thing after the 1980s.' They weren't wrong. Flossing, much like other modern hygiene practices, gained traction in the U.S. not necessarily because people had sudden dental epiphanies, but because associations and corporations pushed for it.In India, on the other hand, dental care never received that kind of promotional push. For generations, brushing twice a day was the gold standard, and that too only in urban households. There were no commercials telling you to slide string between your teeth, nor any syllabus mentioning it in schoolbooks. One commenter summed it up succinctly: 'If it weren't for my chachu, I wouldn't even know what flossing is.'Interestingly, while flossing hasn't taken root, Indians have long embraced another oral hygiene practice — tongue scraping . It's a habit steeped in Ayurvedic tradition and now slowly being 'discovered' by wellness influencers in the West. Ironically, the very people puzzled by our lack of flossing are now adopting our ancient tools for holistic oral care.A user highlighted how bizarre this cultural crossover can be, saying that some in the West have hesitated to use tongue scrapers due to homophobic misconceptions or gag reflex fears. Still, thanks to digital marketing and influencer advocacy, tongue cleaning is having a moment abroad.Even for those who know about flossing, the practicality of the habit is another hurdle. The cost of dental floss in India has reportedly surged — once priced around ₹60, it can now cost ₹200 or more. One user wrote that they eventually switched to a water flosser because, while expensive upfront, it offered long-term ease and freshness that traditional floss couldn't match.Accessibility and affordability remain significant barriers. Unlike the U.S., where dental hygiene is heavily commercialized and linked to insurance systems, India doesn't incentivize routine dental care — financially or socially. As one Redditor cynically observed, in the U.S., sparkling white teeth can be the difference between job offers and judgment, making flossing part of a broader system of cosmetic pressure and insurance dynamics.While flossing may not be an Indian norm, times are changing. With the rise of wellness influencers, dental aesthetics are slowly creeping into mainstream conversations — just like skincare did a few years ago. Younger Indians, exposed to global content and equipped with disposable income, are beginning to view flossing not as an American quirk, but as a self-care practice.Whether or not flossing becomes a staple in Indian households, the Reddit discussion reveals a larger truth: oral hygiene, like most habits, is less about science and more about social influence. And in a globalized world where one viral video can introduce a country to tongue scrapers or jade rollers, the humble dental floss may yet find its place — wedged snugly between India's canines and bicuspids.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India.com
10 minutes ago
- India.com
Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is….
Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is…. Get Rs 2 lakh insurance for just a cost of two tea cups. Know about Pradhan Mantri Suraksha Bima Yojana here. By Joy Pillai Edited by Joy Pillai Advertisement Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is.... Pradhan Mantri Suraksha Bima Yojana: Many people have a habit of drinking tea and smoking cigarettes. This habit affects health and, in the long run, causes serious diseases. But what if we tell you that you can buy insurance worth Rs 2 lakh just by skipping two cups of tea or a cigarette? Today, we are telling you about an insurance scheme that provides financial security at a very low premium. No, it is not a fraud scheme, and there are no hidden charges either, because the scheme is run by the Government of India. The name of this scheme is Pradhan Mantri Suraksha Bima Yojana (PMSBY). Let's know more about the scheme. What Is Pradhan Mantri Suraksha Bima Yojana? Pradhan Mantri Suraksha Bima Yojana is basically an accident insurance scheme which offers accidental death and disability cover on account of an accident. The aim of the scheme is to provide financial strength to economically weaker families. The premium under PMSBY is only Rs. 20 per year. Under this scheme, you can also deposit a premium of Rs. 2 every month. Under this scheme, this amount is deducted from your Aadhaar linked bank account every year. Advertisement === Key Features Of PMSBY If the insured person becomes completely disabled in an accident, then he is eligible to get Rs 2 lakh. In case of a partial accident, Rs 1 lakh is given under the scheme. Advertisement === The insurance can be renewed every year. If the policyholder dies, then this money is given to the family. Who Can Avail The Benefit? People between the ages of 18 to 70 can avail themselves of the benefits of the scheme. Notably, this policy ends automatically on completion of the age of 70 years. Only Indian citizens are eligible for the security insurance scheme. The applicant must have an active bank account in any bank, which is linked to Aadhaar. If your bank account is closed then this policy will also end. The policy cover period is between 1st June to 31st May. What Is The Process Of Applying? To apply for this insurance program, apply at your bank. The bank will provide an application form which, once completed and submitted with the required documents, will initiate the process.


Time of India
an hour ago
- Time of India
Ozempic and Wegovy may cut dementia risk by 45% and manage diabetes, study finds
Source: Reuters A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro- may significantly reduce the risk of developing dementia. The analysis, conducted by Irish researchers and published in JAMA Neurology , involved data from over 164,000 participants and found that these medications reduced the risk of memory-robbing disorders by up to 45 per cent. These findings not only open new avenues for neurological protection but also position GLP-1 drugs as powerful tools in both metabolic and cognitive health management. Study links GLP-1 drugs like Ozempic and Mounjaro to lower dementia risk Researchers from the University of Galway reviewed 26 clinical trials involving 164,531 individuals—65% of whom were men, with an average age of 64. The participants were followed for an average of 31 months. The key discovery: patients taking GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were 45% less likely to develop dementia compared to those on other glucose-lowering medications. Dr. Catriona Reddin, senior study author, said, 'Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo How GLP-1 agonists may protect against dementia Although the exact mechanism remains under investigation, researchers propose several pathways through which GLP-1 medications could shield the brain: Reduced neuroinflammation: These drugs may lower inflammation in the brain, which is known to damage neurons and trigger dementia symptoms. Decrease in amyloid and tau proteins: GLP-1 agonists could suppress the accumulation of toxic proteins linked to Alzheimer's disease. Improved blood vessel health: They may reduce blood pressure and enhance blood flow, preventing vascular dementia. Neurogenesis stimulation: Early research suggests these drugs may promote neural growth in the hippocampus, the brain region essential for memory. GLP-1 drugs may help prevent both diabetes and dementia The new study aligns with earlier research from the University of Florida, which followed 400,000 Americans and reported a 33% lower risk of dementia among GLP-1 users compared to other treatments. This growing body of evidence supports the role of semaglutide and tirzepatide not only in treating type 2 diabetes and obesity but potentially in preventing cognitive decline. Professor Martin O'Donnell, Dean at the University of Galway, emphasised, 'With both diabetes and dementia rising, these findings have major public health implications.' Dementia and diabetes: Twin epidemics in the US The study arrives amid alarming trends: Over 8 million Americans currently live with dementia, with 500,000 new cases diagnosed each year. Diabetes now affects 38 million people in the US; around 12% of the population. According to the Alzheimer's Association, Alzheimer's rates have climbed 25 consecutive years. The intersection of these two epidemics highlights the urgency of therapies that can address both conditions simultaneously. Study highlights need for more GLP-1 brain health data While the findings are promising, researchers caution that more work is needed to confirm the results. Notable limitations include: Lack of data on dementia subtypes like Lewy body and vascular dementia Differences in study design and follow-up durations Unclear long-term cognitive outcomes for different age groups and genders Still, this analysis lays essential groundwork for future research into neurometabolic protection via GLP-1 therapies. Originally celebrated as breakthrough treatments for obesity and diabetes, these medications may now be poised to take on an even broader role in preventing neurodegenerative diseases. As Dr. Reddin concluded, 'This research marks a significant advancement in how we understand the brain benefits of diabetes medications.' This article is based on findings from a study published in JAMA Neurology (July 2024). While the research links GLP-1 drugs like Ozempic and Mounjaro to reduce dementia risk, it is observational and does not prove direct causation. Further studies are needed. Always consult a healthcare provider before making medication decisions. Also Read | 5 coffee routine habits that could be doing more harm than good, say experts
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
CDMOs gear up for peptide boom amid rising demand for weight-loss drugs
As global demand for next-generation weight-loss and diabetes therapeutics surges, India's contract development and manufacturing organisations (CDMOs) are strategically positioning themselves to capture a bigger share of the peptide market, particularly in anticipation of key patent expiries such as that of semaglutide—a blockbuster GLP-1 receptor agonist. India is poised to play a critical role in the global manufacturing of GLP-1 drugs, driven by soaring demand for therapies like semaglutide and tirzepatide. The GLP-1 market is projected to exceed $150 billion by 2030. India's peptide CDMO market, currently estimated at around $80 million, is expected to grow at a CAGR of 14 per cent until 2030. Though the country currently accounts for just 3 per cent of the global peptide CDMO space—valued at $190 billion—the growth momentum is unmistakable, according to Nilaya Varma, Co-founder and Group CEO of Primus Partners. Top Indian players in the space include Glenmark, Cipla, Divi's Laboratories, Themis Medicare, Peptomer Therapeutics, Syngene International, and Sai Life Sciences. Semaglutide patent expiry fuels strategic activity Semaglutide, the active ingredient in drugs such as Ozempic and Wegovy, is owned and produced by Novo Nordisk and is set to go off-patent in India in March 2026. Leading pharmaceutical companies, including Dr Reddy's Laboratories, Sun Pharma, Cipla, Mankind Pharma, Natco Pharma, Lupin, and Biocon, are preparing to launch drugs in this category. These companies are investing in R&D, manufacturing capacity, and collaborations to compete in this rapidly growing market. Anthem Biosciences is experiencing a surge in inquiries for peptide active pharmaceutical ingredients (APIs), including those related to weight loss. 'Semaglutide can be produced through total synthesis or biosynthetic routes. Very few companies in India can manage biosynthetic production—and we are one of them,' said Ganesh Sambasivam, Promoter and Chief Scientific Officer at Anthem. While he declined to confirm whether semaglutide is in active production at Anthem, he hinted that it may be among the peptides currently in development. Syngene highlights technical edge in peptide trials Jayashree Aiyar, Chief Scientific Officer at Syngene International, sees opportunities not just in manufacturing, but also in preclinical and clinical development. 'We've already supported preclinical studies on semaglutide and recently helped a global pharma company with a bioequivalence study using pre-filled pens,' Aiyar said. These studies included developing and validating sensitive LC-MS/MS methods to measure semaglutide plasma levels—a significant technical challenge for peptides. Syngene's case study on semaglutide demonstrates the rigorous planning and execution required for clinical bioequivalence trials involving peptides. With gastrointestinal side effects common among test subjects, the company had to implement robust risk management and continuous patient support mechanisms. On the analytical front, it overcame complex challenges like autosampler carryover and low detection limits through custom-developed chromatography and mass spectrometry protocols. 'While we are not currently manufacturing GLP-1 APIs, we are well-equipped with peptide scale-up and fill–finish capabilities. We continue to invest in technologies to meet future market needs,' Aiyar added. Production and compliance challenges persist However, peptide manufacturing comes with its own set of challenges. 'There are production hurdles involving the availability of protected amino acids, coupling reagents, and advanced purification protocols, particularly for bulk APIs,' Varma noted. These challenges, combined with high utility costs and stringent environmental controls, add pressure to meet international compliance standards. Schemes such as the 2024 Production Linked Incentive (PLI) and Greenfield Bulk Drug Park initiatives are expected to ease some of these bottlenecks. While some CDMOs are already entrenched in the space, others are evaluating the landscape. Kashmik Formulations, for instance, is not currently working on semaglutide or related APIs, nor has it received client inquiries. However, the company sees the patent expiry of semaglutide as a potential inflection point. 'We're open to collaborations with larger players who can provide validated processes,' the company said in a statement. Diabetes burden drives urgency for scalable solutions The spike in demand is closely linked to a global epidemic of lifestyle diseases. Arushi Jain, Director at Akums Drugs & Pharmaceuticals, underscores this urgency. 'Over 100 million Indians are living with diabetes, underlining the need for scalable therapeutic solutions that address root causes such as obesity.' Akums is actively tracking developments in weight-loss APIs. As patents for semaglutide and similar molecules expire, Indian CDMOs are gearing up for a new wave of growth. Equipped with scientific expertise, evolving infrastructure, and an appetite for collaboration, the Indian peptide manufacturing ecosystem is emerging as a vital player in the global fight against obesity and metabolic diseases.